CROI 2025 will cover viral infections, treatments, and potential cures, focusing on HIV, COVID-19, STIs, and hepatitis C. The conference will feature plenary sessions on HIV research, global ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral ...

Top content from CROI 2025 focused on COVID-19 and HIV, including the safety of a vaccine in people taking antiretroviral therapy. Our top content coverage from the Conference on Retroviruses and ...

On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is ...

Findings in HIV highlight AMV technology's versatility, robust immune response, and excellent safety profile, underpinning company's expansion into oncology applications Paris, France – March 13, 2025 ...

The data were presented during an oral abstract session at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) and were also published today in The Lancet. Data will support the ...

The major HIV conference in San Francisco this week coincides with growing fears that budget cuts being pushed by Republicans will gut essential health care services in the United States and worldwide ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 10 March 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company ...

Findings in HIV highlight AMV technology's versatility, robust immune response, and excellent safety profile, underpinning company’s expansion into oncology applications AMVs are a new class of ...